Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Cardiovascular Systems Inc is a medical devices business based in the US. Cardiovascular Systems shares (CSII) are listed on the NASDAQ and all prices are listed in US Dollars. Cardiovascular Systems employs 725 staff and has a trailing 12-month revenue of around $236.2 million.
Our top pick for
Beginners
Our top pick for
Free trades
Our top pick for
Social traders
| Latest market close | $12.93 |
|---|---|
| 52-week range | $12.77 - $36.97 |
| 50-day moving average | $15.15 |
| 200-day moving average | $17.61 |
| Wall St. target price | $21.00 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-0.84 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $12.93 from 2022-09-23
| 1 week (2022-09-16) | -8.49% |
|---|---|
| 1 month (2022-08-25) | -13.40% |
| 3 months (2022-06-24) | -13.63% |
| 6 months (2022-03-25) | -37.51% |
| 1 year (2021-09-24) | -61.22% |
|---|---|
| 2 years (2020-09-25) | -64.53% |
| 3 years (2019-09-25) | 49.49 |
| 5 years (2017-09-25) | 27.75 |
Valuing Cardiovascular Systems stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Cardiovascular Systems's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Cardiovascular Systems's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 177.27. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Cardiovascular Systems's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
| Revenue TTM | $236.2 million |
|---|---|
| Gross profit TTM | $172.8 million |
| Return on assets TTM | -6.63% |
| Return on equity TTM | -14.19% |
| Profit margin | -15.64% |
| Book value | $6.09 |
| Market capitalisation | $578.8 million |
TTM: trailing 12 months
We're not expecting Cardiovascular Systems to pay a dividend over the next 12 months.
Cardiovascular Systems's shares were split on a 1:10 basis on 25 February 2009. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Cardiovascular Systems shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Cardiovascular Systems shares which in turn could have impacted Cardiovascular Systems's share price.
Over the last 12 months, Cardiovascular Systems's shares have ranged in value from as little as $12.77 up to $36.97. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Cardiovascular Systems's is 0.9656. This would suggest that Cardiovascular Systems's shares are less volatile than average (for this exchange).
Cardiovascular Systems, Inc. , a medical technology company, develops and commercializes solutions to treat peripheral and coronary artery diseases in the United States and internationally. The company offers peripheral artery disease products comprising catheter-based platforms to treat various plaque types in above and below the knee, including calcified plaque, as well as address various limitations related with surgical, catheter, and pharmacological treatment alternatives; and peripheral support products. It also provides Diamondback 360 Coronary orbital atherectomy systems (OAS), a coronary artery disease (CAD) product designed to facilitate stent delivery in patients with CAD who are acceptable candidates for percutaneous transluminal coronary angioplasty or stenting due to severely calcified coronary artery lesions. In addition, it offers guidewires, catheters, balloons, embolic protection system, and other OAS support products. Cardiovascular Systems, Inc. has a partnership with Chansu Vascular Technologies, LLC to develop novel peripheral and coronary everolimus drug-coated balloons.
Looking to invest in tech? Here’s how to buy shares in the major tech companies, known as FAANG stocks.
A simple guide to buying stocks in your favorite European soccer team.
Steps to owning and managing JUVE, with 24-hour and historical pricing before you buy.
Steps to owning and managing ASR, with 24-hour and historical pricing before you buy.
Steps to owning and managing BVB, with 24-hour and historical pricing before you buy.
Everything we know about the Lead Real Estate Co. IPO, plus information on how to buy in.
Everything we know about the Third Harmonic Bio IPO, plus information on how to buy in.
Everything we know about the LINKBANCORP IPO, plus information on how to buy in.
Here are the stocks that benefit from inflation, as well as industries to keep an eye on to reduce the impacts of inflation on your portfolio.
We’ve rounded up stats on some of the most popular wheat stocks, along with information on how these stocks compare and how to invest.